[바이오타임즈] ABL Bio (CEO Lee Sang-hoon), a company specializing in bispecific antibodies, announced on the 19th that it had successfully completed the presentation of a preclinical research poster of ABL102, an immuno-oncology drug candidate pipeline, at the American Association for Cancer Research (AACR).
ABL102, a bispecific antibody that targets both ROR1 and 4-1BB, is designed to activate the clustering of 4-1BB depending on the expression of ROR1. Since ROR1 is selectively expressed only in the microtumor environment where target cancer cells exist, it prevents 4-1BB from being activated in normal cells. When used as a single antibody, it is possible to maintain the memory T cell function, which is a unique function of 4-1BB, which prevents recurrence by remembering previously invaded antigens while minimizing the side effects of 4-1BB, which is toxic.
In this preclinical poster, the company explains that these strengths of ABL102 were introduced in detail through excellent data.
According to the announcement, ABL102 showed excellent tumor suppression effect through complete remission (CR) in a mouse model. In an experiment in which the previously exposed tumor was reintroduced to the mouse three months later, the activation of memory T cell function of 4-1BB was demonstrated while the tumor was suppressed for a long time. In addition, in the primate (NHP) model, as a result of a comprehensive safety evaluation including death, body weight, blood, hepatotoxicity, clinical chemical reaction, and pathology of the experimental model, excellent safety was confirmed even at high doses of up to 100 mg/kg, and ABL102 is ROR1 It strongly suggested that it could be a new alternative to the treatment of benign cancer patients.
Lee Sang-hoon, CEO of ABL Bio, said, “As the preclinical data of ABL102 were excellent, conference participants continued to visit and ask questions, so they had a busy schedule throughout the event. As ROR1 is expressed in various types of carcinoma, from solid cancer to hematological cancer, and is an antibody that global big pharmas are paying attention to, we could feel the market’s high interest in ABL102, the first ROR1x4-1BB bispecific antibody conjugated with 4-1BB.” He expressed his feelings about the progress of the 6-day conference.
Meanwhile, ABL Bio’s ABL001 (VEGFxDLL4), ABL111 (Claudin18.2×4-1BB), ABL503 (PD-L1x4-1BB), ABL105 (HER2x4-1BB), ABL202 (ROR1 ADC), ABL301 (a-synxIGF1R), etc. 6 More than seven pipelines are undergoing global clinical trials in the US, China, and Korea, and pipelines such as ABL103 (B7-H4x4-1BB) and ABL104 (EGFRx4-1BB) are also preparing for clinical entry. In addition, research and development of numerous non-clinical pipelines, including ABL603 (Claudin18.2xCD3) and ABL602 (CLL1xCD3), are also actively underway.
[바이오타임즈=김수진 기자] [email protected]
